{"id":"ocrelizumab-dose-2-and-dose-3","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL2108041","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to CD20, ocrelizumab triggers the depletion of B cells, which are involved in the pathogenesis of multiple sclerosis and other autoimmune diseases. This depletion leads to a reduction in disease activity and symptoms.","oneSentence":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:50.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"},{"name":"Primary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT07282574","phase":"PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2026-03-10","conditions":"Progressive Multiple Sclerosis","enrollment":360},{"nctId":"NCT02649985","phase":"PHASE1, PHASE2","title":"PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2016-05-02","conditions":"Multiple Sclerosis, Alzheimer's Disease","enrollment":250},{"nctId":"NCT04466150","phase":"PHASE4","title":"Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2020-08-30","conditions":"Relapsing Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":30},{"nctId":"NCT04998851","phase":"PHASE4","title":"A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-09-16","conditions":"Multiple Sclerosis, Clinically Isolated Syndrome","enrollment":26},{"nctId":"NCT04075266","phase":"PHASE2","title":"A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-01-09","conditions":"Multiple Sclerosis","enrollment":23},{"nctId":"NCT05131984","phase":"","title":"Ocrelizumab Access by Socio-Economic Status","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-11-18","conditions":"Multiple Sclerosis","enrollment":800},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT03972306","phase":"PHASE1","title":"A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-08-12","conditions":"Multiple Sclerosis (MS)","enrollment":134},{"nctId":"NCT04578639","phase":"PHASE3","title":"Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2020-11-02","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":214},{"nctId":"NCT00676715","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07-17","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":220},{"nctId":"NCT02688985","phase":"PHASE3","title":"Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-04-29","conditions":"Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive","enrollment":131},{"nctId":"NCT04295733","phase":"","title":"Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency","status":"COMPLETED","sponsor":"Ospedale Policlinico San Martino","startDate":"2020-02-06","conditions":"Acquired Immunodeficiency","enrollment":98},{"nctId":"NCT04971005","phase":"PHASE2","title":"Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-08-27","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1},{"nctId":"NCT03835728","phase":"PHASE2","title":"Efficacy of Ocrelizumab in Autoimmune Encephalitis","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-01-22","conditions":"Autoimmune Encephalitis","enrollment":3},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT00485589","phase":"PHASE3","title":"A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-06-11","conditions":"Rheumatoid Arthritis","enrollment":613},{"nctId":"NCT03606460","phase":"PHASE3","title":"A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2018-09-14","conditions":"Multiple Sclerosis","enrollment":141},{"nctId":"NCT00779220","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Chugai Pharmaceutical","startDate":"2008-10","conditions":"Rheumatoid Arthritis","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ocrelizumab Dose 2 and Dose 3","genericName":"Ocrelizumab Dose 2 and Dose 3","companyName":"Genentech, Inc.","companyId":"genentech-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Relapsing forms of multiple sclerosis, Primary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}